Two Faces of Heme Catabolic Pathway in Newborns: A Potential Role of Bilirubin and Carbon Monoxide in Neonatal Inflammatory Diseases

Abstract EN

In an infant’s body, all the systems undergo significant changes in order to adapt to the new, extrauterine environment and challenges which it poses.

Fragile homeostasis can be easily disrupted as the defensive mechanisms are yet imperfect.

The activity of antioxidant enzymes, i.e., superoxide dismutase, catalase, and glutathione peroxidase, is low; therefore, neonates are especially vulnerable to oxidative stress.

Free radical burden significantly contributes to neonatal illnesses such as sepsis, retinopathy of premature, necrotizing enterocolitis, bronchopulmonary dysplasia, or leukomalacia.

However, newborns have an important ally—an inducible heme oxygenase-1 (HO-1) which expression rises rapidly in response to stress stimuli.

HO-1 activity leads to production of carbon monoxide (CO), free iron ion, and biliverdin; the latter is promptly reduced to bilirubin.

Although CO and bilirubin used to be considered noxious by-products, new interesting properties of those compounds are being revealed.

Bilirubin proved to be an efficient free radicals scavenger and modulator of immune responses.

CO affects a vast range of processes such as vasodilatation, platelet aggregation, and inflammatory reactions.

Recently, developed nanoparticles consisting of PEGylated bilirubin as well as several kinds of molecules releasing CO have been successfully tested on animal models of inflammatory diseases.

This paper focuses on the role of heme metabolites and their potential utility in prevention and treatment of neonatal diseases.